Back to Results

Pharming Group NV (PHAR)

Featured in High-Growth Small-Cap Stocks Small-Cap Stocks

Pharming Group N.V. is a biopharmaceutical company whose listed security on NASDAQ is a depositary receipt representing the common stock of the issuer. The company develops and commercializes protein replacement therapies and precision medicines focused on rare diseases in the United States, Europe, and other international markets. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor used to treat acute attacks in adult and adolescent patients with hereditary angioedema. Pharming also develops Joenja (leniolisib), an oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome. In addition, the company has a development collaboration and license agreement with Novartis. Founded in 1988, Pharming Group N.V. is headquartered in Leiden, the Netherlands.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PHAR
$14.62
10.3% Upside
Fair
$34.35
159.0% Upside
Bargain
Great
—
—
—
0.0%
July 30, 2026
75.4x
3.5x
2.5x
912.8 M
870.1 M
11.3%
98.4%
6.0
—
450.9%
Valuation • Fair Value

Pharming Group NV (NASDAQ-PHAR) Fair Value by Valuation Model

Compare the primary fair value estimate for Pharming Group NV (NASDAQ-PHAR) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$14.62

Estimated upside of 10.3% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$19.65

Discounted cash flow valuation reference.

Ben Graham Formula Value

$2.05

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$13.82

Earnings power value estimate.

Comps Fair Value

$13.08

Comparable-company valuation reference.

Analyst Price Target

$34.35

Analysts imply upside of 159.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Pharming Group NV (NASDAQ-PHAR) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Pharming Group NV (NASDAQ-PHAR)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

369.5 M

Current operating scale indicator.

Revenue Forecast

405.6 M

Forward revenue estimate.

EBITDA

42.282 M

Current operating profitability reference.

EBITDA Forecast

69.152 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Pharming Group NV (NASDAQ-PHAR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Pharming Group NV (NASDAQ-PHAR)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.76

No elevated caution signal from this screen.

Altman Z-Score

6.0

Relatively strong balance-sheet zone.

FCF / Net Income

450.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Pharming Group NV (NASDAQ-PHAR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Pharming Group NV (NASDAQ-PHAR)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Pharming Group NV (NASDAQ-PHAR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Pharming Group NV (NASDAQ-PHAR) Stock Forecast & Technical Outlook

Review Pharming Group NV (NASDAQ-PHAR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Pharming Group NV (NASDAQ-PHAR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Pharming Group NV (NASDAQ-PHAR) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Pharming Group NV (NASDAQ-PHAR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Pharming Group NV (NASDAQ-PHAR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Pharming Group NV (NASDAQ-PHAR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Pharming Group NV (NASDAQ-PHAR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Pharming Group NV (NASDAQ-PHAR) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

Pharming Group NV (NASDAQ-PHAR) Stock FAQ

Quick answers about Pharming Group NV (NASDAQ-PHAR) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$14.62
Estimated upside 10.3%
Valuation Rating
Undervalued
Estimated upside of 10.3%
Analyst Target
$34.35
Implied upside 159.0%
Financial Health
Great
Current financial-health read

The current fair value estimate for Pharming Group NV (NASDAQ-PHAR) is $14.62. This implies an estimated upside of 10.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 10.3% versus the current market price.

The available analyst price target for Pharming Group NV (NASDAQ-PHAR) is $34.35. The analyst target implies estimated upside of 159.0%.

The current financial health read for Pharming Group NV (NASDAQ-PHAR) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Pharming Group NV (NASDAQ-PHAR) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Pharming Group NV (NASDAQ-PHAR) is 75.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Pharming Group NV is 912.8 M.

The current enterprise value listed for Pharming Group NV is 870.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Pharming Group NV is NASDAQ-PHAR, and the stock is listed on NASDAQ.

Pharming Group NV (NASDAQ-PHAR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Pharming Group NV is 11.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Pharming Group NV is 98.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)